Literature DB >> 33526466

Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.

Tristan Lee1, Jeffrey M Clarke2, Deepali Jain3, Sendhilnathan Ramalingam2, Vishal Vashistha4.   

Abstract

Recent developments in precision oncology have increased the complexity of diagnostic and therapeutic decisions. Here, we broadly review the field of precision oncology and discuss common mutational drivers in non-small cell lung cancer (NSCLC) that directly relate to the diagnosis, evaluation, and treatment of patients with metastatic disease.
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Entities:  

Year:  2021        PMID： 33526466     DOI： 10.3949/ccjm.88a.19148

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  2 in total

1.  Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model.

Authors:  Sha Tian; Yinmei Guo; Jiajun Fu; Zijing Li; Jing Li; Xuefei Tian
Journal:  Comput Math Methods Med       Date:  2022-05-14       Impact factor: 2.809

2.  CRISPR/Cas9-3NLS/sgHMGA2@PDA nanosystem is the potential efficient gene editing therapy for gastric cancer with HMGA2 high expression.

Authors:  Zhouying Wu; Xue Huo; Tingyu Yang; Kun Liu; Ting Wu; Zongqi Feng; Min Wang; Feng Li; Jianchao Jia; Xiaoran Zhang; Wenming Gao; Lan Yu
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.